FindTrial
Sign In

MEK162, MEK inhibitor; oral

DRUG2 trials

Sponsors

Array Biopharma, now a wholly owned subsidiary of Pfizer, Pfizer

Conditions

Epithelial Ovarian CancerFallopian Tube CancerLow-grade Serous Fallopian Tube CancerLow-grade Serous Ovarian CancerLow-grade Serous Peritoneal CancerPeritoneal Cancer

Phase 1

A Study of MEK162 and Paclitaxel in Patients With Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
CompletedNCT01649336
Array Biopharma, now a wholly owned subsidiary of PfizerEpithelial Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Start: 2012-07-31End: 2016-03-31Updated: 2020-09-14

Phase 3

A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer
TerminatedNCT01849874
PfizerLow-grade Serous Fallopian Tube Cancer, Low-grade Serous Ovarian Cancer, Low-grade Serous Peritoneal Cancer
Start: 2013-06-27End: 2022-08-23Updated: 2023-10-30

Related Papers

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer
Clinical Cancer Research2023-08-1521 citations
Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).
Journal of Clinical Oncology2021-05-209 citations
1 MILO/ENGOT-OV11: Phase-3 study of binimetinib versus physician’s choice chemotherapy (PCC) in recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum
2019-09-0116 citations
The MILO (MEK inhibitor in low-grade serous ovarian cancer)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.
Journal of Clinical Oncology2015-05-207 citations
A phase Ib dose-escalation study of binimetinib (MEK162) in combination with weekly paclitaxel in patients with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal cancer.
Journal of Clinical Oncology2015-05-202 citations
The MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ENGOT-ov11 study: A multinational, randomized, open-label phase 3 study of binimetinib (MEK162) versus physician’s choice chemotherapy in patients with recurrent or persistent low-grade serous carcinomas of the ovary, fallopian tube, or primary peritoneum.
Journal of Clinical Oncology2014-05-209 citations